It’s important to note that shares are not forming a chart pattern for investors to watch. For the first quarter, Pfizer stock analysts forecast earnings of 55 cents per share and $14.38 billion in sales. Earnings are audusd forecast news and analysis expected to dive 55% as sales tumble more than 21%. On the flip side, revenue from blood thinner Eliquis and Vyndaqel beat expectations. Vyndaqel treats a condition in which abnormal protein builds up on the heart.
This suggests that while Pfizer’s dividend is high, it may not be in danger of a cut. Based on savvy rules of investing, PFE stock isn’t a buy right now. Promisingly, Pfizer said in February its RSV vaccine, Abrysvo, proved 77.8% effective over two years against lower respiratory tract infection in adults age 60 and older. This is part of an ongoing final-phase study in the Northern and Southern hemispheres. That’s a drop from 88.9% effectiveness over a year, but still shows “durable” effectiveness, Pfizer said in a news release.
- This suggests that while Pfizer’s dividend is high, it may not be in danger of a cut.
- The acquisitions of clinical-stage companies also could offer growth — if acquired pipeline candidates reach the finish line.
- Adria Cimino has no position in any of the stocks mentioned.
Instead, using 2019 revenue of $51 billion offers a more accurate comparison. And from there, we can see potential for significant progress by 2030, with possible revenue growth of about 65%. I would expect momentum to continue through the early 2030s as pipeline programs reach the finish line, adding to revenue. Pfizer (PFE -1.08%) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer’s revenue reach a record level of $100 billion in 2022; the two products made up more than half of that.
The company traces its origins to the founding of Charles Pfizer & Co. in Brooklyn, N.Y., in 1849 by Charles Pfizer and Charles Erhart. The company expanded during the late 1800s and early 1900s, remaining a privately held company until June 1942, when it offered shares of its common stock to the public for the first time. It was the first mass producer of the “miracle drug” penicillin in the 1940s and was generating more than a billion dollars in sales by the early 1970s. Pfizer has become one of the biggest pharmaceutical companies in the world, with a market capitalization of $251.3 billion as of Nov. 3, 2021.
Is Pfizer the Best Dividend Stock for You?
In 2020, Pfizer co-developed with BioNTech SE a vaccine against COVID-19, the virus whose rapid spread prompted the World Health Organization (WHO) to declare a global pandemic in March 2020. On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older. On May 10, 2021, the FDA expanded the EUA for the Pfizer-BioNTech vaccine to include adolescents ages 12–15.
Pfizer also is delivering growth in key leadership areas such as pneumococcal vaccination; in the recent quarter, it had a 95% share of the adult market with Prevnar 20. There is some risk that comes with the stock today simply because of the uncertainty ahead with respect to how well its plan for growing revenue and earnings will pan out. But with a strategy in place and acquisitions helping to bolster its prospects, investors should feel confident that the company is on a good path forward. Since a pandemic is an uncommon situation, we shouldn’t use Pfizer’s revenue levels during peak pandemic times as a comparison point.
Join MarketSurge, Get 80% Off
This month, the European Commission approved Pfizer’s Prevnar 20, a vaccine to help protect babies and children from pneumococcal disease. The company also recently said its new drug Adcetris — courtesy of its $43 billion takeover of Seagen in December — significantly improved overall survival in patients with a form of lymphoma. Pfizer is now angling for Adcentris’ eighth Food and Drug Administration approval.
Pfizer Stock And Recent News
Blood thinner Eliquis generated $6.75 billion in sales, up 4% on a strict, as-reported basis. On Oct. 29, 2021, the FDA extended the EUA for the vaccine to include children ages 5–11.
Revenue from Xeljanz, which treats inflammatory conditions, fell 5% to $1.7 billion. Sales of Enbrel, developed with Amgen (AMGN), toppled 17% to $830 million. As for patent expiration, this, too, is something all pharma companies face at a certain point. So we shouldn’t focus on the losses of exclusivity, but instead on what Pfizer is doing to compensate and grow. Pfizer has paid a quarterly dividend for 341 consecutive quarters — that’s a span of more than 85 years. Another important question for dividend investors to consider is the state of the overall business.
Investing in Pfizer Stock (PFE)
The pharmaceutical company’s EPS Rating, a measure of profitability, is 35 out of a best-possible 99. The EPS Rating compares a stock’s recent and longer-term earnings growth against all other stocks. Trading for 19 times forward earnings estimates, is Pfizer a buy?
Pfizer is classified as a member of the S&P 500 healthcare sector and operates within the biotechnology and pharmaceutical industry. Inc. (MRK), Switzerland-based Roche Holding AG (RHHBY), https://www.forex-world.net/currency-pairs/gbp-aud/ and Eli Lilly and Co. (LLY). Pfizer reported adjusted net income attributable to its common shareholders of $25.2 billion on $81.3 billion in annual revenue in its 2021 fiscal year (FY).
Though it has a booster Covid shot, like rivals Moderna (MRNA) and Novavax (NVAX), analysts don’t expect sales to climb. Investors are encouraged to seek stocks with 20%-25% recent sales and earnings growth. Big institutional investors — who account for up to 70% of all market trades — usually look for stocks https://www.topforexnews.org/news/australia-braces-for-coal-export-ban-as-relations/ with accelerating earnings and sales growth. In fact, Pfizer says its pipeline of cancer drugs could lead to a potential eight new blockbuster medicines by 2030. The company is an expert in making antibody drug conjugates, or ADCs. These targeted medicines send toxic chemicals directly to cancer cells.